Clinical-Pathological Features and Treatment Modalities of Primary Brain Tumors in Tanzania—4 Years of Institutional Experience

Alita Mrema1, Salama Iddy1, Mamsau Ngoma1,2, Nanzoke Mvungi1, Emmanuel Lugina1,2*

1Ocean Road Cancer Institute (ORCI), Dar es Salaam, Tanzania
2Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania
Email: *elugina@yahoo.com

How to cite this paper: Mrema, A., Iddy, S., Ngoma, M., Mvungi, N. and Lugina, E. (2022) Clinical-Pathological Features and Treatment Modalities of Primary Brain Tumors in Tanzania—4 Years of Institutional Experience. Journal of Cancer Therapy, 13, 252-265. https://doi.org/10.4236/jct.2022.135021

Received: March 30, 2022
Accepted: May 23, 2022
Published: May 26, 2022

Copyright © 2022 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
http://creativecommons.org/licenses/by/4.0/ Open Access

Abstract
Background: The profile of primary brain tumors and treatment modalities employed in Tanzania remains largely unknown. The study aimed to describe the baseline clinical-pathological profile and treatment modalities for primary brain tumors in adults treated at the Ocean Road Cancer Institute (ORCI) from 2017 to 2020. Materials and Methods: This was a retrospective study conducted at ORCI by reviewing 61 medical records of patients with primary brain tumors over the age of 15 from January 2017 to December 2020. A structured questionnaire was used to retrieve information on sociodemographic, clinical-pathological characteristics, and treatment modalities. The 2007 WHO classification system and the International Classification of Cancer Diseases (ICD-0-3) were used for classification and diagnosis. The X² test and Fisher’s exact test were used to compare the proportions and an independent t-test was used to compare the means. A P-value less than 0.05 was deemed statistically significant. Results: The mean age of the females was 41.8 years and the mean age of males was 42.9 years. Overall M: F ratio was 1:1.2. Meningioma was the only tumor that was more commonly found in women with M: F of 1:2.1. The most prevalent symptom was headache (57.4%). Glioblastoma (GBM) was the most common tumor among adults (38%), followed by astrocytomas (23%) and meningioma (18%). Approximately 91.8% of all tumors occurred in the supratentorial region. The Frontal lobe was the most common site (29.5%). Approximately 81.9% of patients received surgery. The gross tumor resection (GTR) rate was 26.2%, and the subtotal tumor resection (STR) rate was 55.7%. Roughly 18% of the tumors were inoperable. An estimated 80.3% of respondents received radiation therapy. The radiotherapy technique was 3DCRT in two-thirds of the patients and the rest received conventional 2D radiotherapy. The mean equivalent dose in the 2 Gy fractions (EQD2) was 43.9 Gy. Respondents with low-grade
intracranial tumors were treated with a mean EQD2 of 47.3 Gy, while those with high-grade intracranial tumors were treated with a mean EQD2 of 44.3 Gy and the difference was statistically significant. Only half of the patients who received adjuvant radiotherapy received it concurrently with chemotherapy. Temozolomide was the most widely used cytotoxic medication. **Conclusion:** Mean age of the patients was 41 years old. Most tumors were in the supratentorial area and GBM was the most common tumor. Only meningioma was a bit more common amongst females. Overall, radiotherapy doses and the gross tumor resection rates were low. Concurrent chemotherapy with radiotherapy was given to a few patients.

**Keywords**
Primary Brain Tumor, Clinical Profile, Treatment Modalities, Tanzania

---

1. **Background**

Primary brain tumors are a heterogeneous group of malignant and benign brain parenchymal tumors and the structures around them. Tanzania is ranked as a low human development index (HDI) country in the UN Development Program’s four-level system. There were 330,000 cases of CNS cancer and 227,000 deaths worldwide in 2016, with an increase in age-standardized incidence rates of CNS cancer from 17.3% to 26.9% globally between 1990 and 2016. The top three countries with the highest number of incident cases were China, the USA, and India [1]. These tumors can be classified as grades 1 to 4 (WHO), while grades 1 and 2 are defined as benign tumors, while grades 3 and 4 are defined as malignant tumors [2]. According to Globocan 2018 estimates, the worldwide incidence of age-standardized rates (ASR) of the brain and nervous system cancer in high/very-high HDI (Human Development Index) regions versus low/medium HDI regions was 5.0 and 2.4 for men and 4.0 and 1.7 for women respectively. These incidence rates were about twice as high in high/very high HDI countries as in low/average HDI countries and slightly higher for men than for women [3].

In Tanzania, primary brain tumors are rare, accounting for around 3% of all cancer cases per year (hospital data). They are associated with significant morbidity and mortality due to the disease itself and treatment modalities, placing a greater burden on patients and caregivers [4]. Neuroepithelial tissue tumors are the most common primary intra-axial brain tumors. Gliomas are the most common and are further subdivided into oligodendrogliomas, astrocytomas, ependymomas, and mixed oligoastrocytomas [5].

The treatment of brain cancer is multidisciplinary and patients navigate between the neurosurgeon, radiologist, and oncologist [6]. Ocean Road Cancer Institute (ORCI) specializes in radiotherapy and chemotherapy for cancer patients while surgery is carried out in other centers. There is a paucity of data concerning clinic-pathological profiles of the patients with primary brain tumors in
Tanzania and the treatment modalities used. The purpose of the study was to establish a baseline profile of patients with primary brain tumors in Tanzania.

2. Materials and Methods

2.1. Ethical Statement

Ethical clearance and permission to conduct the study were sought from the Ethical Clearance Board (IRB) of the ORCI. All methods were performed per the ORCI guidelines and regulations. A waiver of informed consent was requested and approved by ORCI Ethical Clearance Board because of the retrospective nature of the study design.

2.2. Study Design and Population

This was a retrospective descriptive study conducted at ORCI. ORCI is the largest cancer hospital in Tanzania. ORCI has specialized in providing radiotherapy and chemotherapy. It has two LINAC teletherapy units, two Cobalt-60 teletherapy units and two high dose rate (HDR) Cobalt-60 brachytherapy units. Approximately 6000 new cancer patients are seen at ORCI annually, out of which approximately less than 3% have a primary brain tumor. Approximately 95% of patients with primary brain tumors in Tanzania who need adjuvant treatment after surgery are usually referred to ORCI. We reviewed medical charts of patients having primary brain tumors who presented at ORCI from January 2017 to December 2020.

2.3. Inclusion and Exclusion Criteria

Patients who were above 14 years of age with histologically or radiologically confirmed primary brain and meninges tumors were included in the study. Patients who had metastatic brain malignancy, primary CNS lymphomas, hematopoietic malignancies, cranial nerve tumors, and primary bone tumors with intracranial extension were excluded from the study.

2.4. Treatment Protocol

All patients had brain MRI. Radiation treatment comprised external beam radiotherapy (EBRT). The radiotherapy technique was either two-dimensional radiotherapy (2DRT) using Cobalt 60 teletherapy units or three-dimensional conformal radiotherapy (3DCRT) using LINAC. Patients who were treated using 3DCRT were immobilized by using thermoplastic masks. Patients who were treated with 2DRT were treated with whole-brain radiotherapy without the thermoplastic masks. We mostly used 2DRT before we acquired LINAC in 2018. Clinical markup was used for 2DRT planning and a CT simulator was used for 3DCRT. Target volumes and organs at risk were contoured when 3DCRT was used. The prescribed dose was 30 Gy/10 fractions when 2DRT was used and it was higher, according to the nature of the tumor when 3DCRT was used. Concurrent chemotherapy with radiotherapy and adjuvant chemotherapy was given according to the histology of the tumor.
2.5. Data Collection and Variables

We extracted data from medical charts by using a self-designed structured questionnaire. The covariates were age, gender, histology, tumor grade, tumor site, symptoms, surgery extent, radiotherapy dose, radiotherapy technique, and the use of concurrent chemo-radiotherapy. A pilot study was conducted to test the validity of the questionnaire and inter-rater reliability was used to assess the reliability of the questionnaire.

2.6. Statistical Methods

SPSS version 21 (SPSS Inc., Chicago, IL) was used for statistical analysis. Continuous variables were summarized and presented as frequency and mean, and we summarized categorical variables as proportions. $X^2$ test and Fisher’s exact test were used to compare proportions and an independent sample t-test was used to compare means. A P-value of less than 0.05 was considered statistically significant.

3. Results

The study recruited 61 patients.

The most commonly affected age group was 15 - 39 years. The mean and median age of the respondents was 42.4 years and 41.4 respectively, with a range of 15 - 73 years. The ratio of females to males was 1:1.2. The mean age of the females was 41.8 years and the mean age of males was 42.9 years, although the difference was not statistically significant by t-test ($P = 0.08$) (Table 1).

The most common histology was Glioblastoma (GBM) (37.7%) and most respondents had a high-grade tumor (66%). About two-thirds of the respondents presented with headaches. The most commonly affected lobe was the frontal lobe (29.5%). About 91.8% of all tumors were supratentorial and 8.2% were infratentorial (Table 2).

GBM was the most common tumor (39.3%) (Figure 1).

Headache was the most common symptom, followed by motor weakness in all affected lobes (Figure 2).

Table 1. Characteristics of respondents (N = 61).

| Variable        | Frequency | (%)  |
|-----------------|-----------|------|
| **Age (Years)** |           |      |
| 15 - 39         | 28        | 45.9 |
| 40 - 59         | 22        | 36.1 |
| 60 - 79         | 11        | 18.0 |
| **Gender**      |           |      |
| Female          | 28        | 45.9 |
| Male            | 33        | 54.1 |
| **ECOG**        |           |      |
| 1               | 11        | 18.0 |
| 2               | 26        | 42.6 |
| 3               | 13        | 21.3 |
| 4               | 11        | 15.0 |

ECOG—Eastern Cooperative Oncology Group.
Table 2. Clinical-pathological characteristics of the study population (N = 61).

| Variable               | Frequency | (%)  |
|------------------------|-----------|------|
| **Grade (n = 50)**     | Low       | 17   | 34.0 |
|                        | High      | 33   | 66.0 |
| **Symptoms**           |           |      |      |
| Headache               |           | 34   | 64.8 |
| Dizziness              |           | 10   | 18.9 |
| Weakness               |           | 18   | 34.0 |
| Seizures               |           | 9    | 17.0 |
| Blindness              |           | 12   | 26.6 |
| Loss of balance        |           | 5    | 9.4  |
| Amnesia                |           | 5    | 9.4  |
| Loss of consciousness  |           | 6    | 11.3 |
| Incontinence           |           | 1    | 1.9  |
| **Affected site**      |           |      |      |
| Parietal               |           | 17   | 27.9 |
| Frontal                |           | 18   | 29.5 |
| Occipital              |           | 3    | 4.9  |
| Posterior fossa        |           | 5    | 8.2  |
| Temporal               |           | 9    | 14.8 |
| Meninges               |           | 1    | 1.6  |
| Thalamus               |           | 3    | 4.9  |
| Corpus callosum        |           | 1    | 1.6  |
| Cerebellum             |           | 4    | 6.6  |

Figure 1. Frequency of primary CNS tumors.

In this series, most of the respondents had subtotal-tumor excision (STR) (55.7%). Respondents with Ependymoma had the highest gross tumor resection (GTR) rate (25%) followed by Astrocytoma (35%). The GTR rate for GBM was about 26%. About 80% of the respondents were given radiotherapy, and for about two-thirds of the respondents who were given adjuvant radiotherapy the
A technique used was 3DCRT. The mean overall EQD2 was 45.8 Gy. About 28.6% of the respondents who were given adjuvant radiotherapy were also given concurrent chemo-radiotherapy and the most common cytotoxic drug used was Temozolamide (87.5%). About 60% of the patients with GBM were given concurrent temozolomide (Table 3).

Respondents with GBM had the highest mean age, and respondents with germinoma had the lowest mean age. Meningioma was more common in females (M:F = 1:2.7). Respondents with meningioma and medulloblastoma were treated with the overall highest mean EQD2 (53 Gy) and respondents with germinoma were treated with the overall lowest mean EQD2 (30 Gy). Among the respondents who were treated with 3DCRT, those who had meningioma were treated with the highest EQD2 (55.9 Gy) (Table 4).

About 82% of the patients had reports of histologic grades. Two-thirds of the tumors had high-grade histology. All GBM and Oligodendrogioma were of high grade. Tumors that had the highest proportions of low-grade histology were astrocytoma (75%), meningioma (71.4%), and brainstem glioma (66.7%) (Table 5).

Patients with high-grade intracranial tumors were treated with a lower dose (EQD2) in comparison to those with high-grade tumors and the difference was statistically significant by t-test (Table 6).

The 3-year OS rate was 18% and the median survival time was 24 months.

4. Discussion
The overall mean age in this study at diagnosis was 42.4 years and the age range was between 15 and 73 years, which is similar to a study by Lapointe et al. [7] but differs from a study done in Ghana by Ekpene et al. [8] showed a small mean age of 32 years (range 2 - 73 years) in patients with primary brain tumors. The higher mean age in our study could be because of the exclusion of pediatric patients.

The female to male ratio was 1:1.2 in the index study. It’s consistent with an
Table 3. Treatment profile of study population (N = 61).

| Variable                      | Frequency | Percentage |
|-------------------------------|-----------|------------|
| Surgery                       |           |            |
| Gross Tumor resection         | 16        | 26.2       |
| Subtotal tumor resection      | 34        | 55.7       |
| No surgery                    | 11        | 18         |
| Radiotherapy                  |           |            |
| Yes                           | 49        | 80.3       |
| No                            | 12        | 19.7       |
| Radiotherapy technique        |           |            |
| (n = 49) 2DRT                 | 14        | 28.6       |
| 3DCRT                         | 35        | 71.4       |
| Concurrent chemotherapy       |           |            |
| (n = 16) Temozolamide         | 14        | 83.3       |
| Vincristine                   | 1         | 5.6        |
| Bevacizumab                   | 1         | 5.6        |
| Radiotherapy dose in 2 Gy fractions (Gy) (n = 49) | | |
| Less than 50 Gy               | 29        | 55.2       |
| Over 50 Gy                    | 20        | 40.8       |

2DRT—Two-dimensional radiotherapy; 3DCRT—Three-dimensional conformal radiotherapy.

Table 4. Mean ages and mean radiotherapy doses of brain tumors in the study population.

| Histology            | Mean age (Years) | M:F | Location (ST/IT) | Mean ETD2 (Gy) Overall (n) | Mean ETD2 (Gy) 2D (n) | Mean ETD2 (Gy) 3DCRT (n) |
|----------------------|------------------|-----|------------------|----------------------------|------------------------|--------------------------|
| GBM                  | 52.2             | 1:1.1 | 22/1            | 43.2 (20)                  | 32.5 (7)               | 49.5 (13)                |
| Astrocytoma          | 34.4             | 1:0.6 | 13/1            | 48.1 (11)                  | 32.5 (2)               | 51.6 (9)                 |
| Oligodendroglioma    | 49.5             | 1:0   | 2/0             | 32.5 (2)                   | 32.5 (2)               | -                        |
| Germinoma            | 17.0             | 1:0   | 1/0             | 30.0 (1)                   | 30.0 (1)               | -                        |
| Ependymoma           | 29.5             | 1:0.3 | 4/0             | 50.8 (3)                   | -                      | 50.8 (3)                 |
| Meningioma           | 42.3             | 1:2.7 | 10/1            | 52.9 (8)                   | 32.5 (1)               | 55.9 (7)                 |
| Glioma               | 30.8             | 1:0.3 | 4/1             | 41.6 (3)                   | 31.2 (1)               | 46.8 (2)                 |
| Medulloblastoma      | 51.0             | 0:1   | 0/1             | 53.0 (3)                   | -                      | 53.0 (1)                 |

ST—Supratentorial; IT—Infratentorial; GBM—Glioblastoma; ETD2—Equivalent dose in 2 Gy fractions.

Table 5. Distribution of histology by grade and GTR rate.

| Histology            | Low grade (%) | High Grade (%) | GTR rate (%) | Total (%) |
|----------------------|---------------|----------------|--------------|-----------|
| GBM                  | 0 (0)         | 22 (100.0)     | 26.1         | 22 (100.0)|
| Astrocytoma          | 9 (75.0)      | 3 (25.0)       | 35.7         | 14 (100.0)|
| Oligodendroglioma    | 0 (0)         | 2 (100.0)      | 0            | 2 (100.0)|
| Ependymoma           | 1 (25.0)      | 3 (75.0)       | 50           | 4 (100.0)|
| Meningioma           | 5 (71.4)      | 2 (28.6)       | 18           | 7 (100.0)|
| Brainstem Glioma     | 2 (66.7)      | 1 (33.3)       | 20           | 3 (100.0)|
| Total (%)            | 17 (34.0)     | 33 (66.0)      | 26.2         | 50 (100.0)|

GBM—Glioblastoma.
Table 6. Association between mean radiotherapy dose (EQD2) and grade of tumors.

| Grade | N  | Mean  | Std. Deviation | Std. Error Mean |
|-------|----|-------|----------------|-----------------|
| Low   | 12 | 47.42 | 10.389         | 2.999           |
| High  | 27 | 44.32 | 13.007         | 2.503           |

$P = 0.02$.

Figure 3. Overall survival rate.

Ekpene et al. study in Ghana [8]. In this study, meningioma was more common in females with M:F ratio of 1:2.7. Other studies have also shown a higher preponderance of women developing meningioma and they linked this preponderance with reproductive and hormonal factors, which predisposes women to be more at risk compared to males [8].

Most of the tumors were of high grade (66.7%) and the most common histology was glioblastoma (GBM) accounting for 39.3%. Similar findings were observed in England by Wanis et al. [9]. Some other studies reported meningioma to be the most common primary brain tumor, which is not in keeping with findings from the index study, possibly because of ethnic, geographical, and environmental differences [10]. The finding that most of the tumors were of high grade could be attributed to the type of patients that are referred to ORCI. ORCI is a tertiary hospital specializing in providing radiotherapy and chemotherapy as adjuvant treatment, while surgery is done in other centers. Patients with high-grade tumors and subtotal resection (STR) are usually referred for adjuvant treatment. That being said, Wanis et al. also found that the majority (two-thirds) of primary brain tumors in England are malignant (high grade) by using a population-based
The most affected site was the frontal lobe. This is consistent with other studies that have also shown frontal lobe dominance, especially in malignant tumors [11]. The most common symptoms were headaches (64.8%), weakness (34%), vision impairment (26.6%), and seizures (17%). Weakness and blindness could be because of the direct effect of tumor or post-surgery sequelae [6]. The headache was also the most common symptom in other studies [11] although other studies showed seizures as the most common presenting symptom [12]. Seizures have been reported to be more frequent in low-grade gliomas and GBM, developing from low-grade astrocytomas as compared to “primary” GBM. A lower incidence of epilepsy in high-grade gliomas may be because of their preferentially white matter location and the incessant tumoral growth that might prevent the development of the “epileptogenic focus”. We might relate a low frequency of epilepsy in these patients to shorter survival from high-grade tumors compared with low-grade tumors [13]. However, in this study, there was no statistically significant association between grade and the occurrence of seizures, perhaps because of the inclusion of meningiomas.

Treatment decisions are based on tumor type, tumor site, malignant potential, the patient’s age, and physical condition. Treatment may require only surveillance, but commonly includes surgery, radiotherapy, chemotherapy, or a combination. The preferred treatment of primary brain tumors is the maximal safe surgical removal of the tumor, followed by radiotherapy and chemotherapy. Benefits of maximal resection include relief of mass effect, decreased tumor burden, improved diagnosis, and a trend toward prolonged survival [14].

In this series, the overall gross tumor resection (GTR) rate for all intracranial tumors was 26.2%, but it ranged from 0% in oligodendrogliomas to 50% in ependymomas. The GTR rate for GBM was 26.1%. In a retrospective study done in Turkey to assess the extent of resection among gliomas, they showed GTR rate was 62.2% [15]. This difference could be because of a difference in the definition of the extent of surgery and variation in resource availability. In the index of study, the extent of resection was determined by using the surgical notes after resection and not the post-operative brain MRI. Post-operative brain MRI is a gold standard in assessing the extent of tumor resection [6]. It will be very interesting to find out how the survival of patients with intracranial tumors at ORCI compares to that in other parts of the world with such low GTR rates.

Radiotherapy can be used as primary treatment or adjuvant treatment following surgical resection. Radiotherapy can improve progression-free survival and overall survival in patients with high-risk low-grade gliomas, defined as patients younger than 40 years with subtotal resection or biopsy, or patients older than 40 years with any type of resection [14]. A total dose of 60 Gy in 30 fractions is usually delivered for GBM, and a dose of 59.4 Gy in 33 fractions is typically given for anaplastic gliomas [16]. A systemic analysis done by Kaur et al. Showed that doses below 50 Gy are inadequate for treating atypical meningioma and
grade three meningioma [17]. In this study, the mean dose in 2 Gy fractions (EQD2) used to treat high-grade intracranial tumors was only 44.5 Gy, while that for low-grade intracranial tumors was 47.3 Gy. Doses of radiation therapy were low, possibly due to advanced disease at the time of presentation, unavailability of 3DCRT in the years before 2018, and poor patient performance status.

Temozolomide was administered to only two-thirds of patients with GBM who also received adjuvant radiotherapy following surgery, possibly as a result of affordability issues. Concurrent use of temozolomide and radiotherapy in high-grade glioma has been associated with improved survival and better outcomes compared to radiotherapy alone as was shown in a study by Stupp et al. which showed temozolomide improved median survival in newly diagnosed GBM when given concurrently with radiotherapy and for maintenance after radiotherapy [18].

5. Conclusion

In conclusion, this is the first single institutional study from Tanzania to elaborate on clinical-pathological features and treatment modalities of patients with primary brain tumors. GBM was the most common tumor among adults. The GTR rate was low and radiotherapy doses were low. Few patients were able to afford temozolomide. The limitations of this research include histological classification without molecular profiling. In addition, the study was subject to reference bias since ORCI is the reference cancer center, which provides mainly radiotherapy and chemotherapy without surgical facilities. Consequently, these outcomes may not be generalized to centers with surgical facilities. We couldn’t gather some information because of the retrospective nature of the study. A population-specific cancer registry is essential for obtaining the exact incidence of primary brain tumors in Tanzania.

Ethics Approval and Consent to Participate

Permission to carry out the study was sought from Ocean Road Cancer Institute Ethics Committee with reference number 10/VOL.XXI/16B. All methods were performed according to ORCI guidelines and regulations.

Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on request.

Acknowledgements

We would not have been able to complete this study without the contributions of the Clinical Oncology, Department of ORCI, and staff of the ORCI cancer registry department, particularly Mr. Jaffari Omary.

Authors’ Contribution

Concept and design: Alita S. Mrema, Emmanuel Lugina, Salama Iddy;
Collection and assembly of data: Salama Iddy, Alita S. Mrema, Emmanuel Lugina;
Data analysis and interpretation: Emmanuel L. Lugina, Alita S. Mrema;
Financial support: Alita S. Mrema, Emmanuel Lugina;
Manuscript writing: Emmanuel L. Lugina, Alita Mrema;
Final approval of manuscript: Alita S. Mrema, Salama Iddy, Emmanuel L. Lugina;
Agree to be accountable for all aspects of work: Alita S. Mrema, Salama, Mamsau Ngoma, Nanzoke Mvungi, and Emmanuel L. Lugina.

Conflicts of Interest
The authors do not disclose any conflict of interest.

References
[1] GBD 2016 Brain and Other CNS Cancer Collaborators (2019) Global, Regional, and National Burden of Brain and Other CNS Cancer, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. The Lancet—Neurology, 18, 376-393.
[2] Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., et al. (2007) The 2007 WHO Classification of Tumors of the Central Nervous System. Acta Neuropathologica, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
[3] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal of Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[4] Lacy, J., Saadati, H. and Yu, J.B. (2012) Complications of Brain Tumors and Their Treatment. Hematology/Oncology Clinics of North America, 26, 779-796. https://doi.org/10.1016/j.hoc.2012.04.007
[5] Jacques, G. and Cormac, O. (2013) Chapter 99—Central Nervous System Tumors. In: Dulac, O., Lassonde, M. and Sarnat, H.B., Handbook of Clinical Neurology, 1st Edition, Elsevier B.V., Amsterdam, 931-958. https://doi.org/10.1016/B978-0-444-52910-7.00015-5
[6] Chandana, S.R., Movva, S., Arora, M. and Singh, T. (2008) Primary Brain Tumors in Adults. American Family Physician, 77, 1423-1430.
[7] Lapointe, S., Perry, A. and Butowski, N.A. (2018) Primary Brain Tumors in Adults. The Lancet, 392, 432-446. https://doi.org/10.1016/S0140-6736(18)30990-5
[8] Baldi, I., Engelhardt, J., Bonnet, C., Bauchet, L., Berteaud, E., Grüber, A., et al. (2018) Epidemiology of Meningiomas. Neurochirurgie, 64, 5-14. https://doi.org/10.1016/j.neuchi.2014.05.006
[9] Wanis, H.A., Möller, H., Ashkan, K. and Davies, E.A. (2021) The Incidence of Major Subtypes of Primary Brain Tumors in Adults in England 1995-2017. Neuro-Oncology, 23, 1371-1382. https://doi.org/10.1093/neuonc/noab076
[10] El Hage, S., Kawtharani, M., Nabha, S., El Masri, J. and Saad, M. (2021) Distribution of Primary Brain Tumor Subtypes in Lebanon: A Multicenter Eleven-Year Study of 695 Patients. Cureus, 13, e17918. https://doi.org/10.7759/cureus.17918
[11] Perkins, A. and Liu, G. (2016) Primary Brain Tumors in Adults: Diagnosis and Treatment. American Family Physician, 93, 211-217.
[12] Andrews, N.B., Ramesh, R. and Odjidja, T. (2003) A Preliminary Survey of Central Nervous System Tumors in Tema, Ghana. *West African Journal of Medicine*, **22**, 167-172.  https://doi.org/10.4314/wajm.v22i2.27942

[13] Rosati, A., Tomassini, A., Pollo, B., Ambrosi, C., Schwarz, A., Padovani, A., *et al.* (2009) Epilepsy in Cerebral Glioma: Timing of Appearance and Histological Correlations. *Journal of Neuro-Oncology*, **93**, 395-400.  https://doi.org/10.1007/s11060-009-9796-5

[14] McKean-Cowdin, R., Razavi, P. and Preston-Martin, S. (2008) Improving Outcomes for People with Brain and Other CNS Tumors. *International Encyclopedia of Public Health*, **2008**, 338-347.  https://doi.org/10.1016/B978-012373960-5.00241-0

[15] Ercan, S. (2019) Effects of Total and Subtotal Glial Tumor Resection on Survival. *Eurasian Journal of Medical Investigation*, **4**, 73-77.  https://doi.org/10.14744/ejmi.2019.74484

[16] Dhermain, F. (2014) Radiotherapy of High-Grade Gliomas: Current Standards and New Concepts, Innovations in Imaging and Radiotherapy, and New Therapeutic Approaches. *Chinese Journal of Cancer*, **33**, 16-24.  https://doi.org/10.5732/cjc.013.10217

[17] Kaur, G., Sayegh, E.T., Larson, A., Bloch, O., Madden, M., Sun, M.Z., *et al.* (2014) Adjuvant Radiotherapy for Atypical and Malignant Meningiomas: A Systematic Review. *Neuro-Oncology*, **16**, 628-636.  https://doi.org/10.1093/neuonc/nou025

[18] Komotar, R.J., Otten, M.L., Moise, G. and Connolly, E.S. (2008) Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review. *Clinical Medicine: Oncology*, **2**, 421-422.  https://doi.org/10.4137/CMO.S390
Appendix

The questionnaire

1) Hospital registration number ..............
2) Age (Years) ............
3) Gender
   a) Female
   b) Male
4) Presenting symptoms (Circle all that apply)
   a) Headache
   b) Dizziness
   c) Weakness
   d) Seizures
   e) Blindness
   f) Loss of balance
   g) Amnesia
   h) Loss of consciousness
   i) Incontinence
5) What lobe of affected?
   a) Parietal
   b) Frontal
   c) Temporal
   d) Occipital
6) Histology ....................
7) Grade .........................
   a) Low grade
   b) High Grade
8) Year of diagnosis .............
9) Type of surgery
   a) Gross tumor resection
   b) Subtotal tumor resection
10) Was adjuvant radiotherapy given?
    a) Yes
    b) No
11) Type of radiotherapy
    a) 2D radiotherapy
    b) Conformal radiotherapy
12) Dose of radiotherapy in 2Gy fractions ...........
13) Was concurrent chemotherapy given?
    a) Yes
    b) No
14) Type of chemotherapy given ....................
15) Date at last contact
16) Status at last contact
a) Alive  
b) Dead  
c) Loss to follow up  

**Abbreviation**  
GBM: Glioblastoma multiforme; EQD2: Equivalent dose in 2Gy fractions; ASR: Age-standardized rate; HDI: Human development Index; CNS: Central nervous system; GTR: Gross tumor resection; STR: Subtotal tumor resection.